Skip to content

Study Details

Testing a Study Drug Bexotegrast for People with Idiopathic Pulmonary Fibrosis

(IRB#: IRB_00171454)

Idiopathic Pulmonary Fibrosis is a disease that causes the lungs to scar and harden. This study will test a drug called Bexotegrast to treat people with this disease. The study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen to be treated with Bexotegrast 160 mg, or Bexotegrast 320 mg, or placebo. The placebo looks like the study drug but does not have the medication. Being in the study requires 8 in-person visits at the study clinic over about 58 weeks. Medical tests will be done to track the health of participants.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 40 years and older
  • Idiopathic Pulmonary Fibrosis diagnosis within the past 7 years
  • If taking nintedanib or pirfenidone, must be on a stable dose for the past 12 weeks
  • If not taking nintedanib or pirfenidone, must not have taken either drug for at least the prior 8 weeks
  • Able to attend in-person at a study clinic

Exclusion Criteria

  • Receiving pharmacologic therapy for pulmonary hypertension
  • Pregnant or breastfeeding
  • Smoking of any kind (not limited to tobacco) within the previous 12 weeks or unwilling to avoid smoking throughout the study

Will I be paid for my time?


For more information contact:

Cassie Larsen


IRB#: IRB_00171454

PI: Mary Beth Scholand

Department: PULMONARY

Approval Date: 2024-02-15 07:00:00

Specialties: Pulmonary

Last Updated: 6/8/23